{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["parsaclisib"]],"indication":"relapsed or refractory marginal zone lymphoma","name":"CITADEL-204","nct_id":"NCT03144674","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=citadel-204-nct03144674. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants who have received prior ibrutinib.","label":"Cohort 1- Closed to Further enrollment","type":"EXPERIMENTAL"},{"description":"Participants who have not received a prior BTK inhibitor.","label":"Cohort 2","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-05-29","type":"ACTUAL"},"conditions":["Lymphoma"],"enrollment":{"count":110,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Parsaclisib","otherNames":["INCB050465"],"type":"DRUG"}],"last_update":"2025-07-11","lead_sponsor":"Incyte Corporation","official_title":"A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-01-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) Based on Lugano Classification Criteria","timeFrame":"Up to approximately 161 weeks"}],"references":[],"start_date":{"date":"2017-12-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)","url":"https://clinicaltrials.gov/study/NCT03144674"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/citadel-204-nct03144674"}